The translational potential of circulating tumour DNA in oncology

Clinical Biochemistry

Volumn 48, Issue 15, 2015, Pages 957-961

  Patel, K M ^a   Tsui, D W Y ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Blood; Cancer; Circulating nucleic acids; DNA; Next generation sequencing; Oncology; Plasma; Urine

Indexed keywords

CHLOROPLAST DNA; TUMOR MARKER; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DNA;

BLOOD SAMPLING; BODY FLUID; DNA DETERMINATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HALF LIFE TIME; HUMAN; NEEDLE BIOPSY; ONCOLOGY; POINT MUTATION; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; BLOOD; CHEMISTRY; DNA SEQUENCE; DRUG RESISTANCE; EARLY CANCER DIAGNOSIS; GENETIC SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MOLECULAR DIAGNOSIS; MUTATION; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS; URINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EARLY DETECTION OF CANCER; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MEDICAL ONCOLOGY; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASMS; PRECISION MEDICINE; SEQUENCE ANALYSIS, DNA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84943663755     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.04.005     Document Type: Review

References (57)

1. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
2. Jung K., Fleischhacker M., Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 2010, 411:1611-1624.
3. Zhang R., Shao F., Wu X., Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 2010, 69:225-231.
4. Gonzalez-Masia J.A., Garcia-Olmo D., Garcia-Olmo D.C. Circulating nucleic acids in plasma and serum (cnaps): applications in oncology. Onco Targets Ther 2013, 6:819-832.
5. Bartoloni E., Ludovini V., Alunno A., Pistola L., Bistoni O., Crino L., et al. Increased levels of circulating DNA in patients with systemic autoimmune diseases: a possible marker of disease activity in Sjogren's syndrome. Lupus 2011, 20:928-935.
6. Ha T.T., Huy N.T., Murao L.A., Lan N.T., Thuy T.T., Tuan H.M., et al. Elevated levels of cell-free circulating DNA in patients with acute dengue virus infection. PLoS One 2011, 6:e25969.
7. Lui Y.Y., Dennis Y.M. Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications. Clin Chem Lab Med 2002, 40:962-968.
8. Antonatos D., Patsilinakos S., Spanodimos S., Korkonikitas P., Tsigas D. Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann N Y Acad Sci 2006, 1075:278-281.
9. Sorenson G.D., Pribish D.M., Valone F.H., Memoli V.A., Bzik D.J., Yao S.L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994, 3:67-71.
10. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005, 102:16368-16373.
11. Dawson S.J., Tsui D.W., Murtaza M., Biggs H., Rueda O.M., Chin S.F., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013, 368:1199-1209.
12. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990.
13. Vogelstein B., Kinzler K.W. Digital PCR. Proc Natl Acad Sci U S A 1999, 96:9236-9241.
14. Yung T.K., Chan K.C., Mok T.S., Tong J., To K.F., Lo Y.M. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009, 15:2076-2084.
15. Forshew T., Murtaza M., Parkinson C., Gale D., Tsui D.W.Y., Kaper F., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012, 4:136ra68.
16. Leary R.J., Kinde I., Diehl F., Schmidt K., Clouser C., Duncan C., et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010, 2:20ra14.
17. McBride D.J., Orpana A.K., Sotiriou C., Joensuu H., Stephens P.J., Mudie L.J., et al. Use of cancer specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 2010, 49:1062-1069.
18. Chen X., Bonnefoi H., Diebold-Berger S., Lyautey J., Lederrey C., Faltin-Traub E., et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999, 5:2297-2303.
19. Otsuka J., Okuda T., Sekizawa A., Amemiya S., Saito H., Okai T., et al. Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer 2004, 14:459-464.
20. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
21. Van Allen E.M., Wagle N., Sucker A., Treacy D.J., Johannessen C.M., Goetz E.M., et al. The genetic landscape of clinical resistance to raf inhibition in metastatic melanoma. Cancer Discov 2014, 4:94-109.
22. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
23. de Bruin E.C., McGranahan N., Mitter R., Salm M., Wedge D.C., Yates L., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014, 346:251-256.
24. Zhang J., Fujimoto J., Zhang J., Wedge D.C., Song X., Zhang J., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014, 346:256-259.
25. Leary R.J., Sausen M., Kinde I., Papadopoulos N., Carpten J.D., Craig D., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012, 4:162ra54.
26. Chan K.C., Jiang P., Zheng Y.W., Liao G.J., Sun H., Wong J., et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013, 59:211-224.
27. Heitzer E., Ulz P., Belic J., Gutschi S., Quehenberger F., Fischereder K., et al. Tumor associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 2013, 5:30.
28. Murtaza M., Dawson S.J., Tsui D.W., Gale D., Forshew T., Piskorz A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
29. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
30. Taly V., Pekin D., El Abed A., Laurent-Puig P. Detecting biomarkers with microdroplet technology. Trends Mol Med 2012, 18:405-416.
31. Oxnard G.R., Paweletz C.P., Kuang Y., Mach S.L., O'Connell A., Messineo M.M., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014, 20:1698-1705.
32. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y.X., Agrawal N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6.
33. Millholland JML S., Fernandez C.A., Shuber A.P. Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing. Res. Rep. Urol. 2012, 4:33-40.
34. Li Y., Zhou X., St John M.A., Wong D.T. RNA profiling of cell-free saliva using microarray technology. J Dent Res 2004, 83:199-203.
35. Pan W., Gu W., Nagpal S., Gephart M.H., Quake S.R. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem 2015, 61:514-522.
36. Soh J., Toyooka S., Aoe K., Asano H., Ichihara S., Katayama H., et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 2006, 119:2353-2358.
37. Sidransky D., Von Eschenbach A., Tsai Y.C., Jones P., Summerhayes I., Marshall F., et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991, 252:706-709.
38. Zhang J., Tong K.L., Li P.K., Chan A.Y., Yeung C.K., Pang C.C., et al. Presence of donor- and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: urinary DNA chimerism. Clin Chem 1999, 45:1741-1746.
39. Botezatu I., Serdyuk O., Potapova G., Shelepov V., Alechina R., Molyaka Y., et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 2000, 46:1078-1084.
40. Su Y.H., Wang M., Brenner D.E., Ng A., Melkonyan H., Umansky S., et al. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn 2004, 6:101-107.
41. Tsui N.B., Jiang P., Chow K.C., Su X., Leung T.Y., Sun H., et al. High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. PLoS One 2012, 7:e48319.
42. Lamy A., Gobet F., Laurent M., Blanchard F., Varin C., Moulin C., et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006, 176:2686-2689.
43. Sjodahl G., Lauss M., Gudjonsson S., Liedberg F., Hallden C., Chebil G., et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 2011, 6:e18583.
44. van Kessel K.E.M., Kompier L.C., de Bekker-Grob E.W., Zuiverloon T.C.M., Vergouwe Y., Zwarthoff E.C., et al. FGFR3 mutation analysis on voided urine samples to reduce cystoscopies and cost in non-muscle invasive bladder cancer surveillance: a comparison of three different strategies. J Urol 2012, 189(5):1676-1681.
45. Zuiverloon T.C., van der Aa M.N., van der Kwast T.H., Steyerberg E.W., Lingsma H.F., Bangma C.H., et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 2010, 16:3011-3018.
46. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
47. Beaver J.A., Jelovac D., Balukrishna S., Cochran R.L., Croessmann S., Zabransky D.J., et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 2014, 20:2643-2650.
48. Wilt T.J., Brawer M.K., Jones K.M., Barry M.J., Aronson W.J., Fox S., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
49. Gormally E., Vineis P., Matullo G., Veglia F., Caboux E., Le Roux E., et al. Tp53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res 2006, 66:6871-6876.
50. Chan K.C., Hung E.C., Woo J.K., Chan P.K., Leung S.F., Lai F.P., et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 2013, 119:1838-1844.
51. Powell S.M., Zilz N., Beazer-Barclay Y., Bryan T.M., Hamilton S.R., Thibodeau S.N., et al. Apc mutations occur early during colorectal tumorigenesis. Nature 1992, 359:235-237.
52. Miller A.J., Mihm M.C. Melanoma. N Engl J Med 2006, 355:51-65.
53. Andre F., Bachelot T., Commo F., Campone M., Arnedos M., Dieras V., et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014, 15:267-274.
54. Rothé F., Laes J.-F., Lambrechts D., Smeets D., Vincent D., Maetens M., et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 2014, 25:1959-1965.
55. Douillard J.Y., Ostoros G., Cobo M., Ciuleanu T., Cole R., McWalter G., et al. Gefitinib treatment in EGFR mutated caucasian nsclc: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014, 9:1345-1353.
56. Bidart J.-M., Thuillier F., Augereau C., Chalas J., Daver A., Jacob N., et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999, 45:1695-1707.
57. Thierry A.R., Mouliere F., Gongora C., Ollier J., Robert B., Ychou M., et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010, 38:6159-6175.